CLARIFICATION iCo Therapeutics Announces Positive Study Results and Significant Advances related to Oral Amphotericin B Program
November 28, 2016, Vancouver, Canada — iCo Therapeutics (“iCo” or “the Company”) (TSX-V: ICO)
November 28, 2016, Vancouver, Canada — iCo Therapeutics (“iCo” or “the Company”) (TSX-V: ICO)
November 24, 2016, Vancouver, Canada — iCo Therapeutics (“iCo” or “the Company”) (TSX-V: ICO)
November 15, 2016, Vancouver, Canada — iCo Therapeutics (“iCo” or “the Company”) (TSX-V: ICO)
August 19, 2016, Vancouver, Canada — iCo Therapeutics (“iCo” or “the Company”) (TSX‐V: ICO)
June 27, 2016, Vancouver, Canada — iCo Therapeutics (“iCo” or “the Company”) (TSX-V: ICO)
April 14, 2016, Vancouver, Canada — iCo Therapeutics (“iCo” or “the Company”) (TSX-V: ICO)
February 17, 2016, Vancouver, Canada — iCo Therapeutics Inc. (“iCo” or “the Company”) (TSX-V:
January 18, 2016, Vancouver, Canada — iCo Therapeutics Inc. (“iCo” or “the Company”) (TSX-V: